环孢素A、霉酚酸酯联合托珠单抗预防脐血移植后移植物抗宿主病的2期试验
该单臂2期试验在中强度双份脐血移植后,将托珠单抗加入环孢素A和霉酚酸酯方案预防急性移植物抗宿主病,共入组45例患者,并与39例既往对照比较。结果显示托珠单抗组移植前综合征减少,但中性粒细胞植入延迟,100天2-4级aGVHD无显著差异,3年生存结局无获益。
要点
- 托珠单抗组移植前综合征发生率为38%,低于对照组的72%(P < .001)。
- 托珠单抗组45天中性粒细胞植入率为93%,低于对照组的97%(P = .009)。
- 100天2-4级aGVHD发生率两组无显著差异(71% vs 82%,P = .11)。
核心结论
- 以托珠单抗为基础的GVHD预防方案延迟了双份脐血移植后的中性粒细胞恢复,未显著降低急性GVHD,且无生存获益。
- 原文结论认为需要探索替代策略以预防双份脐血移植后重度急性GVHD。
研究设计与样本
- 单臂2期临床试验,研究中强度双份脐血移植后加用托珠单抗联合环孢素A和霉酚酸酯预防aGVHD。
- 2018年3月至2021年3月共入组45例患者,中位年龄47岁(范围27-60岁),80%为急性白血病,中位造血干细胞移植合并症指数为2。
- 移植结局与39例既往接受环孢素A和霉酚酸酯的双份脐血移植对照比较,纳入标准相似。
- 试验注册号NCT03434730。
主要发现
- 托珠单抗组移植前综合征发生率为38%(95%CI 24-52),对照组为72%(95%CI 54-84),P < .001。
- 托珠单抗组45天中性粒细胞植入率为93%(中位25.5天),对照组为97%(中位22天),P = .009。
- 主要终点100天2-4级aGVHD发生率两组无显著差异:托珠单抗组71%(95%CI 55-82)vs 对照组82%(95%CI 65-91),P = .11。
- 100天1-4级下消化道aGVHD发生率托珠单抗组有降低趋势:16%(95%CI 7-28)vs 对照组33%(95%CI 19-48),P = .059。
- 两组3年复发率、移植相关死亡率、无进展生存率和总生存率均无显著差异;托珠单抗组呈现肠道微生物组破坏的独特模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Double-unit cord blood transplantation (dCBT) has been associated with high rates of progression-free survival (PFS) in adults with hematologic malignancies but also with relatively high rates of acute graft-versus-host disease (aGVHD). We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate mofetil (MMF) for aGVHD prophylaxis after intermediate-intensity dCBT. A total of 45 patients (median age, 47 years; range, 27-60 years; 80% acute leukemia; median hematopoietic cell transplant-comorbidity index, 2) were enrolled from March 2018 to March 2021. Transplant outcomes were compared with 39 previous CSA and MMF dCBT controls with similar inclusion criteria. Tocilizumab recipients had less pre-engraftment syndrome (38%; 95% confidence interval [CI], 24-52 vs 72%; 95% CI, 54-84; P < .001) but inferior day 45 neutrophil engraftment (93%; median, 25.5 days vs 97%; median, 22 days; P = .009]. The primary end point of day 100 grade 2 to 4 aGVHD was no different between groups (71%; 95% CI, 55-82 with tocilizumab vs 82%; 95% CI, 65-91; P = .11). However, there was a trend toward a lower day 100 incidence of stage 1 to 4 lower gastrointestinal aGVHD with tocilizumab (16%; 95% CI, 7-28 vs 33%; 95% CI, 19-48; P = .059). There were no significant differences in the 3-year incidences of relapse, transplant-related mortality, PFS, or overall survival between the groups. Tocilizumab recipients exhibited a distinct pattern of gut microbiome disruption. In summary, tocilizumab-based GVHD prophylaxis delayed neutrophil recovery without a significant reduction in aGVHD and had no survival benefit after dCBT. Investigation of alternative strategies to prevent severe aGVHD after dCBT is warranted. This trial was registered at www.clinicaltrials.gov as #NCT03434730.
引用
- Politikos I, Brown S, Fein JA, et al. Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation. Blood Adv. 2025. PMID: 40423982. doi:10.1182/bloodadvances.2024014177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。